Despite the previously identified tumor‐related biological prognostic factors, such as cell of origin [16, 38], TP53 aberrations [10, 11], BCL2 and MYC translocations and coexpression phenotype [8, 9, 10], or tumor infiltrating CD4+ lymphocytes [14, 15], age and IPI have remained the main tools in clinical practice to stratify the patients with DLBCL into low‐ and high‐risk groups and different therapies. Here, BCL2 is linked to neoplasm.